Degenerative Mitral Regurgitation: From Prolapse to Precision Therapy
Degenerative mitral valve regurgitation due to mitral valve prolapse affects ≈15 million people globally and is the commonest indication for mitral intervention in high-income countries, but its biology, natural history, and lifetime management are ill defined. This review summarizes current knowledge of the epidemiology, pathophysiology, diagnosis, risk stratification, and lifetime management of degenerative mitral regurgitation, with a focus on areas of uncertainty, recent advances, and emerging research directions. These include translational research focused on determining genetic and cellular drivers of disease progression and mechanistic studies geared to improve detection and prevention of downstream myocardial dysfunction, particularly in high-risk phenotypes, including arrhythmic mitral prolapse. The current landscape of randomized trials and large registries comparing contemporary surgical and transcatheter treatment and strategies to improve patient access to care and outcomes across all patient risk profiles and populations are also discussed.
Authors
- Annetine C. Gelijns (ORCID: https://orcid.org/0000-0001-5389-953X)
- Francesca Nesta Delling (ORCID: https://orcid.org/0000-0002-5224-4096)
- Joanna Chikwe (ORCID: https://orcid.org/0000-0002-6206-4259)
Institutions
- Cedars-Sinai Medical Center (US)
Publication Details
- Journal
- Circulation
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1161/circulationaha.126.081203
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00